Manipal Health IPO Stalls: Subdued Demand and Cautious GMP Drive Investors to Wonder If Subscription is Worth It

Manipal Health IPO Stalls: Subdued Demand and Cautious GMP Drive Investors to Wonder If Subscription is Worth It​

Manipal Health Enterprises’ massive Rs 9,275-crore Initial Public Offering has entered its final day of bidding with investor interest showing a decidedly muted response. The issue, backed by Temasek and prominent healthcare entrepreneur Ranjan Pai, continues to garner cautious attention from the market. As the offering concludes, investors are left questioning whether the premium valuation warrants subscribing to the shares.

Subscription Snapshot as Day 2 Concludes​

By the close of Day 2, the IPO had achieved an overall subscription rate of 45% against the total allotment of 9 crore shares. The retail investor quota was subscribed at 45%, encompassing bids for 1.64 crore shares reserved for this segment.

Subscription levels varied across institutional categories: Qualified Institutional Buyers (QIBs) showed the highest interest, reaching 60% against their 4.87 crore allocation. Non-Institutional Investors (NIIs) subscribed at 14%, suggesting uneven enthusiasm among market segments.

Analyzing the Grey Market Premium​

The Grey Market Premium (GMP) remains modest, with Manipal Health Enterprises commanding a GMP of around Rs 6. This suggests an estimated listing price of Rs 596, which is approximately 1% above the IPO's upper price band of Rs 590.

While the GMP indicates cautious optimism regarding post-listing performance, it is crucial to remember that the grey market remains unofficial and unregulated. It reflects prevailing sentiment but provides no guarantee of listing day gains.

Manipal Health’s Scale and Corporate Strategy​

The public issue includes 13.56 crore fresh equity shares worth Rs 8,000 crore and an Offer for Sale (OFS) totaling 2.16 crore shares valued at Rs 1,275.22 crore. This brings the total IPO size to Rs 9,275.22 crore, with a price band fixed between Rs 560–590 per share.

As of March 31, 2026, Manipal Health has solidified its standing as a major healthcare provider, operating 49 hospitals and managing 13,037 licensed beds across India. The company employs over 24,000 individuals, including more than 11,000 nurses.

How the IPO Proceeds Will Be Deployed​

The funds raised through this offering are earmarked for strategic corporate advancements. A significant portion of Rs 5,378 crore from the fresh issue is dedicated to debt repayment, which will help strengthen the company's balance sheet and reduce interest costs.

Another allocation of Rs 574 crore is designated for acquiring a minority stake in its step-down subsidiary, Sahyadri Hospitals. The remaining proceeds will be allocated toward general corporate purposes and future growth initiatives within the healthcare sector.

Expert Verdict: A Balanced View on Future Growth​

The brokerages maintain a divided stance regarding the listing and subsequent performance of Manipal Health Enterprises. Some analysts are optimistic about the long-term prospects, while others caution against premium valuation risks.

SBI Securities has recommended 'Subscribe,' citing the company's leadership in multi-specialty care, successful acquisition strategy, and planned margin expansion post debt reduction. Anand Rathi Research similarly maintained a rating of 'Subscribe for Long Term.'

However, Arihant Capital and Angel One assigned a 'Neutral' rating. They argue that while the business fundamentals are robust, the market may have already reflected much of the growth potential in the current valuation. Other brokerages highlighted operational efficiency but cautioned that premium pricing may limit near-term listing gains.